Slingshot members are tracking this event:
Exelixis (EXEL) and Bristol-Myers Squibb (BMY) Present Phase 1 Data on CABOMETYX + Opdivo in Genitourinary Tumors at European Society for Medical Oncology 2016 Congress
Do you think this event is important to the companies below? How will it affect their stock price?
Results: From 7/22/15-5/11/16, 24pts (mUC N = 6; bladder urachal N = 4; bladdersquamous cell carcinoma (SCC) N = 3; germ cell tumor (GCT) N = 5; castrate-resistantprostate cancer (CRPC) N = 4; renal cell carcinoma (RCC) N = 1, and trophoblastictumor N = 1) were treated. Median age was 55 (range 35-75), 21 (88%) were male. 9 ptsrequired dose reductions (N = 2 DL1; N = 1 DL2; N = 2 DL3; N = 4 DL4), for PPE G2N = 3 (DL1/2/4)); fatigue G1/2 N = 2 (DL3), diarrhea G2 N = 1 (DL3), lipase/amylaseelevation G3 (DL1), weight loss G1 N = 1 (DL4), and anorexia/dehydration G2 N = 2(DL4). Common treatment-related G1/2 AEs were transaminitis N = 20, diarrheaN = 11, hoarseness N = 7, dysgeusia N = 5, thrombocytopenia N = 5, hyponatremiaN = 5. Grade 3 AEs included neutropenia N = 3 (DL1), fatigue N = 2 DL2, mucositisN = 1 (DL4), vomiting N = 1 (DL3). There were no G4/5 toxicities, no immune-relatedAEs and no DLTs. 18 pts were evaluable for response. ORR was 33% 6/18 (1 CR(bladder SCC); 5 PRs (mUC, RCC, urachal, urethral SCC, CRPC). All responses wereongoing at cutoff. SD 38% 7/18.Conclusions: CaboNivo was well tolerated with no DLTs. Cabo 60mg resulted in moredose reductions due to clinically significant AEs. The recommended dose isCabo40mg/Nivo3mg/kg. Part II of the phase I (triplet with ipilimumab (CaboNivoIpi)is ongoing. Expansion studies in pts with mUC and RCC are planned.
Slingshot Insights Explained
Oct 11, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Cabometyx, Opdivo, Genitourinary Tumors, Phase 1